What Is SS-31 (Elamipretide)? Peptide Profile

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

SS-31, named elamipretide, is a four-residue peptide that solves a problem most compounds cannot: getting inside a mitochondrion and staying there. Its targeting is structural rather than receptor-mediated, which makes it a useful case study in how subcellular delivery can be engineered.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

Key points

Length: four amino acids — one of the shortest peptides in research use.
Series: Szeto-Schiller aromatic-cationic peptides.
Targeting principle: cardiolipin binding in the inner mitochondrial membrane, aided by membrane potential.
No receptor: the mechanism is physicochemical, not ligand-receptor.
Literature: extensive, across cardiac, neural and ageing models; clinical development has been pursued.

How the targeting works

Most peptides cannot cross a plasma membrane, let alone reach a specific organelle. SS-31 does so through its residue pattern: alternating aromatic and cationic amino acids. Three properties follow:

Membrane permeability without a transporter, from the combination of charge and aromatic character.
Electrophoretic accumulation. The inner mitochondrial membrane carries a large negative potential on the matrix side. A cationic peptide is drawn across it, concentrating the molecule.
Retention by cardiolipin binding. Cardiolipin is a distinctive phospholipid largely restricted to this membrane, and association with it anchors the peptide where it arrives.

That combination gives targeting without a receptor. It is also the honest limit of the mechanism: anything that depolarises mitochondria reduces accumulation, so the peptide reaches healthy mitochondria more readily than severely damaged ones. The 2025 review in the International Journal of Molecular Sciences sets out the current mechanistic picture.

Why cardiolipin is the right thing to bind

Cardiolipin is not an incidental structural lipid. Several respiratory chain complexes require it for proper assembly and function, and it participates in the organisation of supercomplexes. Cardiolipin is also oxidised under oxidative stress, and that oxidation is associated with loss of respiratory function and with release of cytochrome c.

So a peptide that binds cardiolipin is positioned at a point where membrane lipid state and respiratory function intersect. That is the published rationale for why effects turn up in such varied models: the target is a shared piece of mitochondrial machinery rather than a tissue-specific receptor.

Published research

Study	Model	Reported observation
Whitson et al., 2021	Aged mouse heart	Attenuation of age-associated post-translational modifications of heart proteins
Zhao et al., 2019	LPS-challenged mice	Improvement in mitochondrial, synaptic and memory measures in that model
Tung et al., 2025	Review	Structure, mechanism and development status

The 2021 heart paper is methodologically the most interesting of the three. Rather than reporting a functional endpoint alone, it measures post-translational modifications of proteins — a molecular readout closer to the proposed mechanism. Studies that connect a mechanism to a molecular signature, instead of jumping to a behavioural outcome, are more useful for evaluating whether the mechanistic story holds.

The interpretive caution

SS-31 appears in papers across cardiology, neurology, nephrology, ageing and ferroptosis research. Breadth like that can be read two ways. It is consistent with acting on machinery common to all tissues. It is also the pattern produced when a compound is widely available and inexpensive to test, so it gets tried in many models and the positive results are published.

Distinguishing the two requires looking at whether a given paper demonstrated target engagement in its system, or only observed an effect after administration. The former supports the mechanism; the latter is compatible with it but does not establish it.

Handling in the lab

Consideration	Note
Solubility	Cationic and short — readily water-soluble
Storage of powder	Sealed, −20 °C, protected from light and moisture
Surface adsorption	Cationic peptides bind negatively charged surfaces; glass and some plastics cause real losses at low concentration
Vehicle controls	Essential — mitochondrial assays are sensitive to buffer composition
Identity confirmation	MS is straightforward at four residues; check the HPLC trace for synthesis impurities

One point specific to this peptide: because accumulation depends on mitochondrial membrane potential, any manipulation that affects potential — an uncoupler, a respiratory inhibitor, severe stress in the model — also changes how much peptide reaches the target. In a protocol combining SS-31 with such an agent, the order and timing of addition is part of the result, not a detail. Concentration maths: peptide reconstitution calculator.

Our SS-31 (elamipretide) research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report.

Open questions

How does accumulation differ between healthy and depolarised mitochondria in the same tissue?
Does cardiolipin binding alter membrane organisation itself, or only protect it from oxidation?
Which of the many reported model effects have been accompanied by direct target-engagement evidence?

What is Humanin?
What is MOTS-c?
NAD+ compared with MOTS-c

Frequently asked questions

What is SS-31?

SS-31, also known as elamipretide, is a synthetic tetrapeptide belonging to the Szeto-Schiller series. It is described as cell-permeable and as accumulating in the inner mitochondrial membrane, where it associates with the phospholipid cardiolipin.

What does the SS in SS-31 stand for?

Szeto-Schiller, after Hazel Szeto and Peter Schiller, whose laboratories developed the series of aromatic-cationic peptides to which it belongs. The number is the series designation.

How does a peptide get inside a mitochondrion?

The published explanation is its alternating aromatic and cationic residue pattern, which allows it to cross membranes without a transporter and to be drawn into the inner mitochondrial membrane by the membrane potential, where it binds cardiolipin.

What is cardiolipin and why does it matter?

Cardiolipin is a phospholipid largely confined to the inner mitochondrial membrane. It is required for the proper function of several respiratory chain complexes. Its restricted distribution is what gives a cardiolipin-binding peptide its mitochondrial targeting.

Is elamipretide the same compound as SS-31?

Yes. Elamipretide is the assigned nonproprietary name; SS-31 is the original research designation. Both appear in the literature, sometimes in the same paper.

References

Tung C, et al. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. Int J Mol Sci. 2025. PMID: 39940712 https://pubmed.ncbi.nlm.nih.gov/39940712/
Whitson JA, et al. Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins. Geroscience. 2021. PMID: 34480713 https://pubmed.ncbi.nlm.nih.gov/34480713/
Zhao W, et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation. 2019. PMID: 31747905 https://pubmed.ncbi.nlm.nih.gov/31747905/